014570 — Korean Drug Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMicro CapContrarian

Annual income statement for Korean Drug Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	66,789	74,466	79,984	81,375	73,001
Cost of Revenue
Gross Profit	28,689	31,065	34,517	37,350	34,401
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	56,290	63,200	65,655	63,349	63,863
Operating Profit	10,500	11,266	14,329	18,026	9,138
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	9,240	11,321	14,685	8,265	4,994
Provision for Income Taxes
Net Income After Taxes	7,360	9,042	11,809	-4,917	2,995
Net Income Before Extraordinary Items
Net Income	7,360	9,042	11,809	-4,917	2,995
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	7,360	9,042	11,809	-4,917	2,995
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	717	828	1,095	-456	277
Dividends per Share